It is a fundamental principle in all serum therapy that to obtain the best results the serum must be given early in the disease. This statement holds true regardless of whether one is using antitoxic or antibacterial serum. During the past decade there have appeared in American and British medical literature a goodly number of reports on the successful use of refined and concentrated antipneumococcus serum in the treatment of pneumococcic pneumonia. The majority of these reports have dealt with pneumococcus type I infections. More recently, however, a number of articles have appeared, reporting favorable results with serum in the treatment of other types of pneumococcic pneumonia. Promising figures have been submitted for the serum treatment of types II, V, VII, VIII and XIV. The most significant feature of these reports on serotherapy is that they are all, without exception, favorable. I cannot recall a single skeptical article since the
CECIL RL. EFFECTS OF VERY EARLY SERUM TREATMENT IN PNEUMOCOCCUS TYPE I PNEUMONIA. JAMA. 1937;108(9):689–692. doi:10.1001/jama.1937.02780090001001
Customize your JAMA Network experience by selecting one or more topics from the list below.